

## Description of CiNA Public Use Dataset

**The NAACCR CiNA-Public Dataset** is a new CiNA product that was first available for 1995-2013 data. The goal behind producing the CiNA Public Use Dataset is to provide faster, streamlined access to the CiNA data in order to increase CiNA data use and, ultimately, reduce the burden of cancer. The data will be available annually after publication of the CiNA monographs; generally in the summer.

The CiNA Public Use Dataset is a publically accessible, non-confidential data set with a limited number of variables, available in the SEER\*Stat program. Access requires only a signed Data Use Agreement for access. There are other CiNA databases with more extensive variable set that require a proposal review, NAACCR IRB approval, and a “yes” consent by each participating registry. The CiNA Public Use the variable list is included at the end of this document. Many variables are recoded from the reported data for ease of use and standardization of analysis. There are no treatment variables available in the CiNA Public Use Dataset.

The dataset is comprised of two datasets. One allows a user to generate counts, rates and trends within the SEER\*Stat system. This dataset includes age in the 19 age group categories. The second dataset allows the user to export the data as a case-listing to allow regression and other analysis in standard, statistical programs. This second dataset includes both age and site as categorical variables for US combined and Canada combined. A researcher will be able to access both data sets in the same SEER\*Stat session but will only be able to export data from registries that have provided consent. SEER\*Stat provides automatic cell suppression of <6 and scrambles the Patient IDs. *At this time, the database allowing exporting is still under development.*

Additional details about the CiNA Public Use Dataset are provided in this document. If you have questions about the NAACCR CiNA Public Dataset, please contact Recinda Sherman, Manager of Research and Data Use at [rsherman@naaccr.org](mailto:rsherman@naaccr.org) or 217-698-0800 x6.

## **Data Use Agreement for Researcher Access to the Public Use Data Set NAACCR CiNA-Public Dataset**

These data are provided for the sole purpose of statistical reporting and analysis only. By using these data, you signify your agreement to comply with the following:

1. There will be no attempt to learn the identity of any person included in these data. If the identity of any person is discovered inadvertently, no disclosure or other use of the identity will be made, **and I will notify NAACCR.**  
**Initials required:** \_\_\_\_\_
2. The identification or contact of individuals is prohibited. I will not discuss in any manner, with any unauthorized person, information that would lead to identification of individuals described in the Data furnished by NAACCR.  
**Initials required:** \_\_\_\_\_
3. I will not attempt either to link—**or permit others to link**—the data with individually identified records in another database.  
**Initials required:** \_\_\_\_\_
4. I will not either release—**or permit others to release**—the data—in full or in part—to any person. I will not share my password for data access with any other individuals. All members of a research team who have access to the data must sign this data-use agreement.  
**Initials required:** \_\_\_\_\_
5. I will not use—or permit others to use—the data in any way other than for statistical reporting and analysis for public health research purposes. I must notify NAACCR if I discover that there has been any other use of the data.  
**Initials required:** \_\_\_\_\_
6. I agree that all data provided shall remain the sole property of NAACCR and may not be copied or reproduced in any form or manner without NAACCR's prior written consent.  
**Initials required:** \_\_\_\_\_
7. I will cite the source of information in all publications. The appropriate citation is associated with the data file used.  
**Initials required:** \_\_\_\_\_
8. Uses of these data do not constitute an endorsement of the user's opinion or conclusions by NAACCR, or any central registry in US or Canada, and none should be inferred.  
**Initials required:** \_\_\_\_\_
9. I understand that calculating rates or other statistics based on small numbers can raise statistical issues concerning accuracy and usefulness. I will use appropriate caution when presenting and interpreting results based on less than 20 cases.  
**Initials required:** \_\_\_\_\_
10. I agree that any and all reports or analyses of the Data shall contain only aggregate data and no report of the Data containing statistical cells with less than six (6) subjects shall be released.  
**Initials required:** \_\_\_\_\_

My signature indicates that I agree to comply with the above stated provisions.

First Name:  
Organization:  
Phone:  
Date:

Last Name:  
Email:  
Signature:

Questions or issues, please contact Recinda Sherman, [rsherman@naaccr.org](mailto:rsherman@naaccr.org).

## **Citation**

Please reference to the source of these data in any published document as indicated in SEER\*Stat session.

For example:

NAACCR Incidence - CiNA Public File, 1995-2015 (which includes data from CDC's National Program of Cancer Registries (NPCR), CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results (SEER) Registries), North American Association of Central Cancer Registries.

## **Technical Documentation**

The NAACCR CiNA-Public Dataset is distributed through SEER\*Stat and contains individual records of cancer incidence among US and Canada residents diagnosed from 1995 – 2015. Confidentiality is maintained by aggregating data within individual records into categories, the number of which depends on whether analysis is run on individual states/registries or nation/North America.

The purpose of releasing cancer surveillance data is to inform public health decision making. Cancer rates are often needed for subgroups or for small populations in order to understand the burden of cancer in these groups or areas. But working with small numbers has two problems 1) working with small numbers, particularly linking with external data, has the potential for confidentiality breaches; and 2) small numbers raise statistical issues regarding the accuracy and, ultimately, the usefulness of the data.

- To preserve confidentiality of the data, data will be automatically suppressed for counts less than 6 based on potentially linkable variables (registry, sex, age, race, race/ethnicity, year of diagnosis and site). Please note, counts less than six may be released for other variables including behavior, stage or histology. However, these variables are not considered identifying variables.
- For issues of statistical stability, we advise caution in interpreting rates and other results based on fewer than 25 cases.

## **Software**

SEER\*Stat statistical software is a standard tool for analysis of cancer-related data. SEER\*Stat is distributed with the CiNA Public Dataset. Additional information on SEER\*Stat is available on the NCI, SEER site: <http://seer.cancer.gov/seerstat/>. Tutorials are available here: <http://seer.cancer.gov/seerstat/tutorials/>. Delay factors, survival statistics, and prevalence are not currently available for the CiNA Public Dataset.

## **Representation**

To be included in the CiNA Public dataset, a central registry from the US or Canada must meet specific data quality standards. All Gold and Silver NAACCR-certified central registries are eligible for inclusion in the CiNA Public dataset. Each central registry must also consent to the use of their data in the CiNA Public dataset. A current list of certified

registries is available here: <https://www.naaccr.org/certified-registries/>. Registries may have not been certified in prior years, but if their data quality improves over time, their data is included in CiNA. However, not all states meet the data quality criteria for each year and will have zero counts for those years. Current CiNA Public Use dataset contains 46 states plus DC and PR for the US, and 12 Canadian provinces covering 93% of the US and 64% of the Canada population.

## **Data Collection**

Cancer registry data is collected in an on-going, systematic, and standardized process. In Canada, the cancer registry collection program is overseen by the Canadian Council of Cancer Registries. In the US, there are two cancer registry collection programs—the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER Program) and the Center for Disease Control’s National Program of Cancer Registries (NPCR). Data for all three programs is collected in a coordinated process from hospitals and other medical facilities, including inpatient, outpatient, and standalone facilities. The data is collected or overseen by certified tumor registrars (CTRs) who are highly trained medical professionals to ensure complete and high quality data collection. The International Classification of Disease-Oncology (ICD-O) coding system is used to code topography (primary site) and morphology (histologic characteristics) of the collected cancers. Additional coding information is available in the NAACCR Data Standards & Data Dictionary (Volume II) available here: <https://www.naaccr.org/data-standards-data-dictionary/>.

Please note, the variables available in the CiNA Public Dataset are a subset of the full variable list collected. Many variables in the CiNA Public Dataset are aggregated and recoded for analysis.

## **Cancer Coding Changes Over Time**

Several definitional changes occurred in some histology and behavior codes in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. One category of change between ICD-O-2 and ICD-O-3 is the manner in which leukemias and lymphomas are classified and coded. Although conversion of histology codes from ICD-O-2 to ICD-O-3 for cases diagnosed prior to 2001 helps minimize these differences, some minor differences may still exist, particularly with respect to some relatively rare lymphocytic cancers that can be coded to either leukemia or lymphoma.

Starting with ICD-O-3, several myelodysplastic diseases and syndromes are considered malignant, and, therefore, are now reportable for cases diagnosed in 2001 and later and are included in these data. Leukemias that represent a disease progression from one of the myelodysplastic diseases or syndromes diagnosed in 2001 and forward are no longer reportable.

For pediatric cancers, differences in incidence rates may be due to changes between the second and third edition of the International Classification of Childhood Cancers

(ICCC). Two changes in the ICCC-3 classification are main contributors to this change. 1) Burkitt lymphoma and unspecified lymphoma, which were separated from non-Hodgkin lymphoma previously are combined with non-Hodgkin lymphoma; 2) Some lymphomas, which were grouped in the miscellaneous lymphoreticular neoplasms previously, are now included in the non-Hodgkin lymphoma category. Pilocytic astrocytoma is considered to have uncertain behavior in the published version of ICD-O-3, but is reportable as a malignant cancer in North America. Including the childhood astrocytomas in the category of malignant brain tumors may introduce differences between childhood brain cancer rates in North America compared to other areas of the world that may not include these tumors as malignant.

In addition, mesothelioma and Kaposi sarcoma cases are reported as separate categories. This change has little or no impact on most rates for specific cancers.

## Variable List

Demographic	State/Province
Demographic	Recode: Country
Demographic	Sex
Demographic	Recode: Age
Demographic	Recode: Race
Demographic	Recode: Hispanic
Cancer ID	Recode: Central Seq #
Cancer ID	Dx date year only
Cancer ID	Recode: Behavior
Cancer ID	Recode: Primary Site plus with Meso & KS
Cancer ID	Recode: ICC
Cancer ID	Recode: CBTRUS for brain
Cancer ID	Recode: Histology
Cancer ID	Recode: Summary Stage
Cancer ID	Laterality
Cancer ID	Grade
Cancer ID	Diagnostic confirmation
Cancer ID	Recode: Report Source <i>CBTRUS brain and CSN histologic groupings—Under development</i>
<i>Derived</i>	
Derived	MP using IARC rules & SEER
Derived	County-Level Urban/Rural Status Code
Derived	County-Level Poverty Code
<i>Derived</i>	<i>SES Composite (SEER)—under development</i>

## Variable Codes:

*State:* Name of state/province (Will include only high quality registries following CiNA monograph standards)

*Country:* 2 codes (US, Canada)—Derived code

*Sex:* T (includes all categories), M, F, unk

*Age:* 5-year aggregates; 0-4, 5-9,...75-79, 80-84, 85+, **no unknown age**

*Race:* (US only)

National: W, B, API, AIAN (AIAN is based on CHDSA counties only; recoded into race variable), Unk; and W, B, O, unk. Race suppressed following CiNA monograph standards (<6 in numerator).

*Race/ethnicity:*

Hispanic All Races, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Other, Non-Hispanic Unknown Race, Unknown Hispanic (based on NHIA). Race/ethnicity suppressed following CiNA monograph standards (<6 in numerator).

*Central Seq #:* variable collapsed

One primary only, 1<sup>st</sup> of 2 or more primaries; 2<sup>nd</sup> of 2 or more primaries; 3<sup>rd</sup> of 3 or more primaries, 4<sup>th</sup> of 4 or more primaries; 5<sup>th</sup> of 5 or more primaries; 6<sup>th</sup> or more of 6 or more primaries

*Year of Diagnosis:* 1995-2013

*Behavior:*

Benign, Borderline, In situ, Malignant, Only Malignant in ICD-O-3, No longer Reportable in ICD-O-3, Only malignant 2010+

*Primary Site (03):* based on ICD-O-3 regardless of diagnosis date; suppression rules apply

All Sites

Oral Cavity and Pharynx

Lip

Tongue

Salivary Gland

Floor of Mouth

Gum and Other Mouth

Nasopharynx

Tonsil

Oropharynx

Hypopharynx

Other Oral Cavity and Pharynx

Digestive System

Esophagus

Stomach

Small Intestine

Colon and Rectum

Colon excluding Rectum

Cecum

Appendix

Ascending Colon

Hepatic Flexure

Transverse Colon

Splenic Flexure

Descending Colon

Sigmoid Colon

Large Intestine, NOS

Rectum and Rectosigmoid Junction

Rectosigmoid Junction

Rectum

Anus, Anal Canal and Anorectum

Liver and Intrahepatic Bile Duct

Liver

Intrahepatic Bile Duct

Gallbladder

Other Biliary

Pancreas

Retroperitoneum

Peritoneum, Omentum and Mesentery

Other Digestive Organs



Respiratory System

Nose, Nasal Cavity and Middle Ear

Larynx

Lung and Bronchus

Pleura

Trachea, Mediastinum and Other

Respiratory Organs

Bones and Joints

Soft Tissue including Heart

Skin excluding Basal and Squamous

Melanoma of the Skin

Other Non-Epithelial Skin

Breast

Female Genital System

Cervix Uteri

Corpus and Uterus, NOS

Corpus Uteri

Uterus, NOS

Ovary

Vagina

Vulva

Other Female Genital Organs

Male Genital System

Prostate

Testis

Penis

Other Male Genital Organs

Urinary System

Urinary Bladder

Kidney and Renal Pelvis

Ureter

Other Urinary Organs

Eye and Orbit

Brain and Other Nervous System

Brain

Cranial Nerves Other Nervous System

Endocrine System

Thyroid

Other Endocrine including Thymus

Lymphoma

Hodgkin Lymphoma

Hodgkin - Nodal

Hodgkin - Extranodal

Non-Hodgkin Lymphoma

NHL - Nodal

NHL - Extranodal

Myeloma

Leukemia

Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Other Lymphocytic Leukemia

Myeloid and Monocytic Leukemia

Acute Myeloid Leukemia

Acute Monocytic Leukemia

Chronic Myeloid Leukemia

Other Myeloid/Monocytic Leukemia

Other Leukemia

Other Acute Leukemia

Aleukemic, Subleukemic and NOS

Mesothelioma

Kaposi Sarcoma

Miscellaneous

*Histology (03):* based on ICD-O-3 regardless of diagnosis date

8000/0: Neoplasm, benign  
8000/1: Neoplasm, uncertain whether benign or malignant  
8000/2: Neoplasm, in situ  
8000/3: Neoplasm, malignant  
8001/0: Tumor cells, benign  
8001/1: Tumor cells, uncertain whether benign or malignant  
8001/3: Tumor cells, malignant  
8002/3: Malignant tumor, small cell type  
8003/1  
8003/3: Malignant tumor, giant cell type  
8004/0  
8004/3: Malignant tumor, spindle cell type  
8005/1  
8005/3: Malignant tumor, clear cell type  
8010/0: Epithelial tumor, benign  
8010/1  
8010/2: Carcinoma in situ, NOS  
8010/3: Carcinoma, NOS  
8011/2: Epithelioma, in situ  
8011/3: Epithelioma, malignant  
8012/2: Large cell carcinoma in situ  
8012/3: Large cell carcinoma, NOS  
8013/3: Large cell neuroendocrine carcinoma  
8014/2  
8014/3: Large cell carcinoma with rhabdoid phenotype  
8015/3: Glassy cell carcinoma  
8020/2  
8020/3: Carcinoma, undifferentiated type, NOS  
8021/3: Carcinoma, anaplastic type, NOS  
8022/2: Pleomorphic carcinoma in situ  
8022/3: Pleomorphic carcinoma  
8030/2: Giant cell and spindle cell carcinoma in situ  
8030/3: Giant cell and spindle cell carcinoma  
8031/2: Giant cell carcinoma in situ  
8031/3: Giant cell carcinoma  
8032/2: Spindle cell carcinoma in situ  
8032/3: Spindle cell carcinoma  
8033/2: Pseudosarcomatous carcinoma, in situ  
8033/3: Pseudosarcomatous carcinoma

8034/3: Polygonal cell carcinoma  
8035/3: Carcinoma with osteoclast-like giant cells  
8040/1: Tumorlet, NOS  
8040/3: Tumorlet, malignant  
8041/2: Small cell carcinoma in situ  
8041/3: Small cell carcinoma, NOS  
8042/2: Oat cell carcinoma in situ  
8042/3: Oat cell carcinoma  
8043/3: Small cell carcinoma, fusiform cell  
8044/3: Small cell carcinoma, intermediate cell  
8045/3: Combined small cell carcinoma  
8046/2: Non-small cell carcinoma in situ  
8046/3: Non-small cell carcinoma  
8050/0  
8050/2: Papillary carcinoma in situ  
8050/3: Papillary carcinoma, NOS  
8051/2: Verrucous papilloma in situ  
8051/3: Verrucous carcinoma, NOS  
8052/2: Papillary squamous cell carcinoma, non-invasive  
8052/3: Papillary squamous cell carcinoma  
8053/2  
8053/3: Papillary squamous cell carcinoma, inverted  
8060/3  
8070/2: Squamous cell carcinoma in situ, NOS  
8070/3: Squamous cell carcinoma, NOS  
8071/2: Squamous cell carcinoma in situ, keratinizing, NOS  
8071/3: Squamous cell carcinoma, keratinizing, NOS  
8072/2: Squamous cell CIS, large cell, nonkeratinizing  
8072/3: Squamous cell ca., large cell, nonkeratinizing  
8073/2: Squamous cell CIS, small cell, nonkeratinizing  
8073/3: Squamous cell ca., small cell, nonkeratinizing  
8074/2: Squamous cell carcinoma in situ, spindle cell  
8074/3: Squamous cell carcinoma, spindle cell  
8075/2: Squamous cell carcinoma in situ, adenoid  
8075/3: Squamous cell carcinoma, adenoid  
8076/2: Squamous cell CIS with questionable stromal invasion  
8076/3: Squamous cell carcinoma, micro-invasive  
8077/2: Squamous intraepithelial neoplasia, grade III  
8077/3: Squamous cell ca. & Grade III  
8078/3: Squamous cell carcinoma with horn formation  
8080/2: Queyrat erythroplasia

8080/3: Queyrat erythroplasia, malignant  
8081/2: Bowen disease  
8081/3: Bowen disease, malignant  
8082/3: Lymphoepithelial carcinoma  
8083/2: Basaloid squamous cell carcinoma in situ  
8083/3: Basaloid squamous cell carcinoma  
8084/3: Squamous cell carcinoma, clear cell type  
8090/2: Basal cell carcinoma in situ  
8090/3: Basal cell carcinoma, NOS  
8091/2: Multicentric basal cell carcinoma in situ  
8091/3: Multifocal superficial basal cell carcinoma  
8092/3: Infiltrating basal cell carcinoma, NOS  
8093/3: Basal cell carcinoma, fibroepithelial  
8094/2: Basosquamous carcinoma in situ  
8094/3: Basosquamous carcinoma  
8095/3: Metatypical carcinoma  
8097/2  
8097/3: Basal cell carcinoma, nodular  
8098/3: Adenoid basal cell carcinoma  
8100/3: Trichoepithelioma, malignant  
8101/3  
8102/3: Trichilemmocarcinoma  
8103/0  
8103/3: Pilar tumor, malignant  
8110/3: Pilomatrix carcinoma  
8120/0  
8120/2: Transitional cell carcinoma in situ  
8120/3: Transitional cell carcinoma, NOS  
8121/2: Transitional cell carcinoma in situ, inverted, NOS  
8121/3: Schneiderian carcinoma  
8122/2  
8122/3: Transitional cell carcinoma, spindle cell  
8123/2: Basaloid carcinoma in situ  
8123/3: Basaloid carcinoma  
8124/2: Cloacogenic carcinoma in situ  
8124/3: Cloacogenic carcinoma  
8130/2: Papillary transitional cell carcinoma, non-invasive  
8130/3: Papillary transitional cell carcinoma  
8131/2: Transitional cell carcinoma in situ, micropapillary  
8131/3: Transitional cell carcinoma, micropapillary  
8140/0: Adenoma, NOS

8140/1: Atypical adenoma  
8140/2: Adenocarcinoma in situ  
8140/3: Adenocarcinoma, NOS  
8141/3: Scirrhous adenocarcinoma  
8142/2  
8142/3: Linitis plastica  
8143/2: Superficial spreading adenocarcinoma in situ  
8143/3: Superficial spreading adenocarcinoma  
8144/2: Adenocarcinoma in situ, intestinal type  
8144/3: Adenocarcinoma, intestinal type  
8145/2: Carcinoma in situ, diffuse type  
8145/3: Carcinoma, diffuse type  
8146/0: Monomorphic adenoma  
8146/3: Monomorphic adenocarcinoma  
8147/2  
8147/3: Basal cell adenocarcinoma  
8148/2: Glandular intraepithelial neoplasia, grade III  
8148/3: Glandular neoplasia, malignant, Grade III  
8149/3  
8150/3: Islet cell carcinoma  
8151/3: Insulinoma, malignant  
8152/3: Glucagonoma, malignant  
8153/3: Gastrinoma, malignant  
8154/3: Mixed islet cell and exocrine adenocarcinoma  
8155/3: Vipoma  
8156/3: Somatostatinoma, malignant  
8160/2: Bile duct adenocarcinoma in situ  
8160/3: Cholangiocarcinoma  
8161/3: Bile duct cystadenocarcinoma  
8162/2  
8162/3: Klatskin tumor  
8170/2: Hepatocellular carcinoma in situ  
8170/3: Hepatocellular carcinoma, NOS  
8171/3: Hepatocellular carcinoma, fibrolamellar  
8172/0  
8172/3: Hepatocellular carcinoma, scirrhous  
8173/3: Hepatocellular carcinoma, spindle cell variant  
8174/3: Hepatocellular carcinoma, clear cell type  
8175/3: Hepatocellular carcinoma, pleomorphic type  
8180/2  
8180/3: Combined hepatocellular ca. & cholangiocarcinoma

8190/3: Trabecular adenocarcinoma  
8200/2: Adenoid cystic carcinoma in situ  
8200/3: Adenoid cystic carcinoma  
8201/2: Cribriform carcinoma in situ  
8201/3: Cribriform carcinoma  
8202/0: Microcystic adenoma  
8202/3  
8210/2: Adenocarcinoma in situ in adenomatous polyp  
8210/3: Adenocarcinoma in adenomatous polyp  
8211/2: Tubular adenocarcinoma in situ  
8211/3: Tubular adenocarcinoma  
8212/2  
8212/3  
8213/2: Serrated adenocarcinoma, in situ  
8213/3: Serrated adenocarcinoma  
8214/3: Parietal cell carcinoma  
8215/3: Adenocarcinoma of anal glands  
8220/2: Adenocarcinoma in situ in adenomatous polyposis coli  
8220/3: Adenocarcinoma in adenomatous polyposis coli  
8221/2: Adenoca. in situ in mult. adenomatous polyposis coli  
8221/3: Adenocarcinoma in mult. adenomatous polyposis coli  
8230/2: Duct carcinoma in situ, solid type  
8230/3: Solid carcinoma, NOS  
8231/3: Carcinoma simplex  
8240/2: Carcinoid tumor, in situ  
8240/3: Carcinoid tumor, malignant  
8241/2  
8241/3: Enterochromaffin cell carcinoid  
8242/0  
8242/3: Enterochromaffin-like cell tumor, malignant  
8243/2  
8243/3: Goblet cell carcinoid  
8244/3: Composite carcinoid  
8245/2  
8245/3: Adenocarcinoid tumor  
8246/2: Neuroendocrine carcinoma in situ  
8246/3: Neuroendocrine carcinoma  
8247/2: Merkel cell carcinoma in situ  
8247/3: Merkel cell carcinoma  
8248/3: Apudoma  
8249/3: Atypical carcinoid tumor

8250/2: Bronchiolo-alveolar adenocarcinoma in situ  
8250/3: Bronchiolo-alveolar adenocarcinoma  
8251/3: Alveolar adenocarcinoma  
8252/2: Bronchiolo-alveolar carcinoma, non-mucinous, in situ  
8252/3: Bronchiolo-alveolar carcinoma, non-mucinous  
8253/2: Bronchiolo-alveolar carcinoma, mucinous, in situ  
8253/3: Bronchiolo-alveolar carcinoma, mucinous  
8254/3: Bronchiolo-alveolar ca., mucinous & non-mucinous  
8255/2: Adenocarcinoma in situ with mixed subtypes  
8255/3: Adenocarcinoma with mixed subtypes  
8260/0: Papillary adenoma, NOS  
8260/1  
8260/2: Papillary adenocarcinoma in situ, NOS  
8260/3: Papillary adenocarcinoma, NOS  
8261/2: Adenocarcinoma in situ in villous adenoma  
8261/3: Adenocarcinoma in villous adenoma  
8262/2: Villous adenocarcinoma in situ  
8262/3: Villous adenocarcinoma  
8263/2: Adenocarcinoma in situ in tubulovillous adenoma  
8263/3: Adenocarcinoma in tubulovillous adenoma  
8264/3  
8270/0: Chromophobe adenoma  
8270/1: Chromophobe adenoma, borderline  
8270/2  
8270/3: Chromophobe carcinoma  
8271/0: Prolactinoma  
8271/1  
8271/3: Prolactinoma, malignant  
8272/0: Pituitary adenoma, NOS  
8272/1: Pituitary, borderline malignancy  
8272/3: Pituitary carcinoma, NOS  
8280/0: Acidophil adenoma  
8280/3: Acidophil carcinoma  
8281/0: Mixed acidophil-basophil adenoma  
8290/0: Oxyphilic adenoma  
8290/2: Oxyphilic adenocarcinoma in situ  
8290/3: Oxyphilic adenocarcinoma  
8300/0: Basophil adenoma  
8300/3: Basophil carcinoma  
8310/0  
8310/2: Clear cell adenocarcinoma in situ



8310/3: Clear cell adenocarcinoma, NOS  
8312/2: Renal cell carcinoma in situ, NOS  
8312/3: Renal cell carcinoma  
8313/3: Clear cell adenocarcinofibroma  
8314/3: Lipid-rich carcinoma  
8315/2  
8315/3: Glycogen-rich carcinoma  
8316/2: Cyst-associated renal cell carcinoma in situ  
8316/3: Cyst-associated renal cell carcinoma  
8317/3: Renal cell carcinoma, chromophobe type  
8318/3: Renal cell carcinoma, sarcomatoid  
8319/2  
8319/3: Collecting duct carcinoma  
8320/2  
8320/3: Granular cell carcinoma  
8321/3  
8322/3: Water-clear cell adenocarcinoma  
8323/0: Mixed cell adenoma  
8323/2: Mixed cell adenocarcinoma in situ  
8323/3: Mixed cell adenocarcinoma  
8325/3: Metanephric adenomacarcinoma  
8330/2: Follicular adenocarcinoma in situ  
8330/3: Follicular adenocarcinoma, NOS  
8331/3: Follicular adenocarcinoma well differentiated  
8332/3: Follicular adenocarcinoma trabecular  
8333/3: Fetal adenocarcinoma  
8334/0  
8335/2: Macrofollicular carcinoma in situ  
8335/3: Follicular carcinoma, minimally invasive  
8336/3  
8337/3: Insular carcinoma  
8340/2: Papillary carcinoma in situ, follicular variant  
8340/3: Papillary carcinoma, follicular variant  
8341/0  
8341/2: Papillary microcarcinoma in situ  
8341/3: Papillary microcarcinoma  
8342/3: Papillary carcinoma, oxyphilic cell  
8343/2: Papillary carcinoma, encapsulated, in situ  
8343/3: Papillary carcinoma, encapsulated  
8344/2  
8344/3: Papillary carcinoma, columnar cell

8345/3: Medullary carcinoma with amyloid stroma  
8346/3: Mixed medullary-follicular carcinoma  
8347/3: Mixed medullary-papillary carcinoma  
8350/3: Nonencapsulated sclerosing carcinoma  
8360/1: Multiple endocrine adenomas  
8360/3  
8361/3  
8370/0  
8370/2: Adrenal cortical carcinoma in situ  
8370/3: Adrenal cortical carcinoma  
8372/0  
8380/2: Endometrioid adenocarcinoma in situ  
8380/3: Endometrioid carcinoma  
8381/2  
8381/3: Endometrioid adenofibroma, malignant  
8382/2: Endometrioid adenoca in situ, secretory variant  
8382/3: Endometrioid adenocarcinoma, secretory variant  
8383/3: Endometrioid adenocarcinoma, ciliated cell variant  
8384/2: Adenocarcinoma, endocervical type, in situ  
8384/3: Adenocarcinoma, endocervical type  
8390/2: Skin appendage carcinoma in situ  
8390/3: Skin appendage carcinoma  
8392/3: Syringofibroadenocarcinoma  
8400/2: Sweat gland adenocarcinoma in situ  
8400/3: Sweat gland adenocarcinoma  
8401/2: Apocrine adenocarcinoma in situ  
8401/3: Apocrine adenocarcinoma  
8402/2: Nodular hidradenoma, in situ  
8402/3: Nodular hidradenoma, malignant  
8403/3: Malignant eccrine spiradenoma  
8405/3: Papillary hidradenocarcinoma  
8406/3: Papillary syringadenocarcinoma  
8407/2  
8407/3: Sclerosing sweat duct carcinoma  
8408/3: Eccrine papillary adenocarcinoma  
8409/2: Eccrine poroma, in situ  
8409/3: Eccrine poroma, malignant  
8410/2: Sebaceous adenocarcinoma in situ  
8410/3: Sebaceous adenocarcinoma  
8413/2: Eccrine adenocarcinoma, in situ  
8413/3: Eccrine adenocarcinoma

8420/2  
8420/3: Ceruminous adenocarcinoma  
8430/2: Mucoepidermoid carcinoma in situ  
8430/3: Mucoepidermoid carcinoma  
8440/0  
8440/2: Cystadenocarcinoma in situ  
8440/3: Cystadenocarcinoma, NOS  
8441/0  
8441/2: Serous cystadenocarcinoma in situ, NOS  
8441/3: Serous cystadenocarcinoma, NOS  
8442/1: Serous cystadenoma, borderline malignancy  
8442/2: Serous cystadenocarcinoma in situ  
8442/3: Proliferating serous carcinoma  
8443/3: Clear cell cystadenocarcinoma  
8444/3: Clear cell cystic tumor, malignant  
8450/2: Papillary cystadenocarcinoma in situ, NOS  
8450/3: Papillary cystadenocarcinoma, NOS  
8451/1: Papillary cystadenoma, borderline malignancy  
8451/3  
8452/0  
8452/1  
8452/2  
8452/3: Solid pseudopapillary carcinoma  
8453/2: Intraductal papillary-mucinous ca., non-invasive  
8453/3: Intraductal papillary-mucinous carcinoma, invasive  
8460/2: Papillary serous cystadenocarcinoma in situ, NOS  
8460/3: Papillary serous cystadenocarcinoma  
8461/2: Serous surface papillary carcinoma, in situ  
8461/3: Serous surface papillary carcinoma  
8462/1: Serous papillary cystic tumor, borderline malignancy  
8462/2: Serous papillary cystadenocarcinoma in situ  
8462/3: Papillary serous cystadenocarcinoma  
8463/3: Serous surface papillary carcinoma  
8470/2: Mucinous cystadenocarcinoma, non-invasive  
8470/3: Mucinous cystadenocarcinoma, NOS  
8471/2: Papillary mucinous cystadenocarcinoma in situ, NOS  
8471/3: Papillary mucinous cystadenocarcinoma  
8472/1: Mucinous cystic tumor of borderline malignancy  
8472/2: Mucinous cystic adenocarcinoma in situ  
8472/3: Mucinous cystadenocarcinoma  
8473/1: Papillary mucinous cystadenoma, borderline malignancy.

8473/2: Papillary mucinous cystadenocarcinoma, in situ  
8473/3: Papillary pseudomucinous cystadenocarcinoma  
8480/2: Mucinous adenocarcinoma in situ  
8480/3: Mucinous adenocarcinoma  
8481/2: Mucin-producing adenocarcinoma in situ  
8481/3: Mucin-producing adenocarcinoma  
8482/3: Mucinous adenocarcinoma, endocervical type  
8490/0: Signet ring cell tumor, benign  
8490/2: Signet ring cell carcinoma in situ  
8490/3: Signet ring cell carcinoma  
8500/2: Intraductal carcinoma, noninfiltrating, NOS  
8500/3: Infiltrating duct carcinoma, NOS  
8501/2: Comedocarcinoma, non-infiltrating  
8501/3: Comedocarcinoma, NOS  
8502/2: Secretory carcinoma in situ of breast  
8502/3: Secretory carcinoma of breast  
8503/2: Noninfiltrating intraductal papillary adenocarcinoma  
8503/3: Intraductal papillary adenocarcinoma with invasion  
8504/2: Noninfiltrating intracystic carcinoma  
8504/3: Intracystic carcinoma, NOS  
8507/2: Intraductal micropapillary carcinoma  
8507/3: Ductal carcinoma, micropapillary  
8508/2: Cystic hypersecretory carcinoma in situ  
8508/3: Cystic hypersecretory carcinoma  
8510/2: Medullary carcinoma in situ, NOS  
8510/3: Medullary carcinoma, NOS  
8512/2: Medullary carcinoma in situ with lymphoid stroma  
8512/3: Medullary carcinoma with lymphoid stroma  
8513/2  
8513/3: Atypical medullary carcinoma  
8514/2  
8514/3: Duct carcinoma, desmoplastic type  
8520/2: Lobular carcinoma in situ  
8520/3: Lobular carcinoma, NOS  
8521/2: Ductular carcinoma in situ  
8521/3: Infiltrating ductular carcinoma  
8522/2: Intraductal and lobular in situ carcinoma  
8522/3: Infiltrating duct and lobular carcinoma  
8523/2: Intraductal with other types of carcinoma in situ  
8523/3: Infiltrating duct mixed with other types of ca.  
8524/2: Lobular CIS with other CIS

8524/3: Infiltrating lobular mixed with other types of ca.  
8525/2  
8525/3: Polymorphous low grade adenocarcinoma  
8530/3: Inflammatory carcinoma  
8540/2: Paget disease, mammary, in situ  
8540/3: Paget disease, mammary  
8541/2: Paget disease in situ and intraductal carcinoma  
8541/3: Paget disease and infiltrating duct carcinoma  
8542/2: Paget disease in situ, extra mammary (except bone)  
8542/3: Paget disease, extramammary  
8543/2: Paget disease in situ and intraductal carcinoma  
8543/3: Paget disease and intraductal carcinoma  
8550/2: Acinar cell carcinoma in situ  
8550/3: Acinar cell carcinoma  
8551/3: Acinar cell cystadenocarcinoma  
8560/2: Squamous cell CIS and glandular papilloma  
8560/3: Adenosquamous carcinoma  
8561/0  
8561/3: Warthin tumor, malignant  
8562/2: Epithelial-myoepithelial carcinoma in situ  
8562/3: Epithelial-myoepithelial carcinoma  
8570/2: Adenocarcinoma in situ with squamous metaplasia  
8570/3: Adenocarcinoma with squamous metaplasia  
8571/3: Adenocarcinoma w. cartilaginous & osseous metaplasia  
8572/0: Adenoma with spindle cell metaplasia  
8572/3: Adenocarcinoma with spindle cell metaplasia  
8573/2: Adenocarcinoma in situ with apocrine metaplasia  
8573/3: Adenocarcinoma with apocrine metaplasia  
8574/2: Adenocarcinoma in situ with neuroendocrine differentiation  
8574/3: Adenocarcinoma with neuroendocrine differentiation  
8575/2  
8575/3: Metaplastic carcinoma, NOS  
8576/3: Hepatoid adenocarcinoma  
8580/2: Thymoma, in situ, NOS  
8580/3: Thymoma, malignant, NOS  
8581/2  
8581/3: Thymoma, type A, malignant  
8582/2  
8582/3: Thymoma, type AB, malignant  
8583/3: Thymoma, type B1, malignant  
8584/2

8584/3: Thymoma, type B2, malignant  
8585/3: Thymoma, type B3, malignant  
8586/3: Thymic carcinoma, NOS  
8588/3: Spindle epithelial tumor with thymus-like element  
8589/3: Carcinoma showing thymus-like element  
8590/3: Sex cord-gonadal stromal tumor, malignant, NOS  
8591/3  
8592/3  
8593/3: Malignant Stromal tumor, with sex cord elements  
8600/3: Thecoma, malignant  
8602/3: Sclerosing stromal tumor, malignant  
8620/2  
8620/3: Granulosa cell tumor, malignant  
8621/3: Granulosa cell-theca cell tumor, malignant  
8622/3: Juvenile granulosa cell tumor, malignant  
8623/3: Sex cord tumor with annular tubules, malignant  
8630/3: Androblastoma, malignant  
8631/3: Sertoli-Leydig cell tumor, poorly differentiated  
8632/3: Gynandroblastoma, malignant  
8633/3  
8634/3: Sertoli-Leydig, poor diff. w. heterologous elements  
8640/2  
8640/3: Sertoli cell carcinoma  
8642/3  
8650/2  
8650/3: Leydig cell tumor, malignant  
8670/2  
8670/3: Steroid cell tumor, malignant  
8680/0: Paraganglioma, benign  
8680/1: Paraganglioma, NOS  
8680/3: Paraganglioma, malignant  
8682/1  
8683/0  
8683/1  
8683/3: Gangliocytic paraganglioma, malignant  
8690/0  
8690/1: Glomus jugulare tumor, NOS  
8690/3: Glomus jugulare tumor, malignant  
8692/3: Carotid body tumor, malignant  
8693/1: Extra-adrenal paraganglioma, NOS  
8693/3: Extra-adrenal paraganglioma, malignant

8700/0  
8700/3: Pheochromocytoma  
8710/2  
8710/3: Glomangiosarcoma  
8711/0: Glomus tumor, NOS  
8711/3: Glomus tumor, malignant  
8712/0  
8713/0  
8713/3  
8720/0: Pigmented nevus, NOS  
8720/2: Melanoma in situ  
8720/3: Malignant melanoma, NOS  
8721/2: Nodular melanoma, in situ  
8721/3: Nodular melanoma  
8722/2: Balloon cell melanoma, in situ  
8722/3: Balloon cell melanoma  
8723/2: Melanoma in situ, regressing  
8723/3: Malignant melanoma, regressing  
8726/0: Magnocellular nevus  
8726/1  
8726/3: Malignant melanoma in magnocellular nevus  
8727/3: Dysplastic nevus, malignant  
8728/0  
8728/1: Meningeal melanocytoma  
8728/2  
8728/3: Meningeal melanomatosis  
8730/2: Amelanotic melanoma, in situ  
8730/3: Amelanotic melanoma  
8740/2: Melanoma in situ in junctional nevus  
8740/3: Malignant melanoma in junctional nevus  
8741/2: Precancerous melanosis, NOS  
8741/3: Malignant melanoma in precancerous melanosis  
8742/2: Lentigo maligna  
8742/3: Lentigo maligna melanoma  
8743/2: Superficial spreading melanoma, in situ  
8743/3: Superficial spreading melanoma  
8744/2: Acral lentiginous melanoma, in situ  
8744/3: Acral lentiginous melanoma, malignant  
8745/2: Desmoplastic melanoma, in situ  
8745/3: Desmoplastic melanoma, malignant  
8746/2: Mucosal lentiginous melanoma in situ

8746/3: Mucosal lentiginous melanoma  
8750/2  
8750/3  
8760/2: Melanoma in situ in compound nevus  
8760/3: Malignant melanoma in compound nevus  
8761/2: Melanoma in situ in giant pigmented nevus  
8761/3: Malignant melanoma in giant pigmented nevus  
8770/2: Epithelioid and spindle cell melanoma in situ  
8770/3: Mixed epithelioid and spindle cell melanoma  
8771/2: Epithelioid cell melanoma in situ  
8771/3: Epithelioid cell melanoma  
8772/0  
8772/2: Spindle cell melanoma in situ, NOS  
8772/3: Spindle cell melanoma, NOS  
8773/3: Spindle cell melanoma, type A  
8774/2  
8774/3: Spindle cell melanoma, type B  
8780/2  
8780/3: Blue nevus, malignant  
8790/3: Cellular blue nevus, malignant  
8800/0: Soft tissue tumor, benign  
8800/3: Sarcoma, NOS  
8801/3: Spindle cell sarcoma  
8802/3: Giant cell sarcoma  
8803/3: Small cell sarcoma  
8804/3: Epithelioid sarcoma  
8805/3: Undifferentiated sarcoma  
8806/3: Desmoplastic small round cell tumor  
8810/0: Fibroma, NOS  
8810/3: Fibrosarcoma, NOS  
8811/1  
8811/3: Fibromyxosarcoma  
8812/3: Periosteal fibrosarcoma  
8813/3: Fascial fibrosarcoma  
8814/3: Infantile fibrosarcoma  
8815/0: Solitary fibrous tumor  
8815/1  
8815/3: Solitary fibrous tumor, malignant  
8820/0: Elastofibroma  
8821/1: Aggressive fibromatosis  
8821/3: Aggressive fibromatosis, malignant



8822/2  
8822/3: Abdominal fibromatosis, malignant  
8823/3: Desmoplastic fibrosarcoma  
8824/0  
8824/1  
8824/3: Myofibroma, malignant  
8825/0: Myofibroblastoma  
8825/1: Myofibroblastic tumor, NOS  
8825/2  
8825/3: Myofibroblastoma, malignant  
8826/3: Angiomyofibroblastoma, malignant  
8830/0: Fibrous histiocyoma, benign  
8830/1  
8830/3: Fibrous histiocyoma, malignant  
8831/0  
8831/3: Histiocyoma, NOS, malignant  
8832/3: Dermatofibrosarcoma, NOS  
8833/3: Pigmented dermatofibrosarcoma protuberans  
8835/1  
8835/3: Malignant plexiform fibrohistiocytic tumor  
8836/1  
8836/3: Malignant angiomatoid fibrous histiocyoma  
8840/0  
8840/3: Myxosarcoma  
8841/1  
8841/3: Angiomyxoma, malignant  
8842/0  
8842/3: Ossifying fibromyxoid tumor, malignant  
8850/0: Lipoma, NOS  
8850/1: Atypical lipoma  
8850/3: Liposarcoma, NOS  
8851/0: Fibrolipoma  
8851/3: Liposarcoma, well differentiated  
8852/3: Myxoid liposarcoma  
8853/3: Round cell liposarcoma  
8854/0  
8854/3: Pleomorphic liposarcoma  
8855/3: Mixed type liposarcoma  
8856/0: Intramuscular lipoma  
8856/3  
8857/0

8857/3: Fibroblastic liposarcoma  
8858/3: Dedifferentiated liposarcoma  
8860/3: Angiomyoliposarcoma  
8861/0: Angiolipoma, NOS  
8861/3  
8870/0  
8870/3  
8880/3  
8881/1  
8890/0: Leiomyoma, NOS  
8890/3: Leiomyosarcoma, NOS  
8891/3: Epithelioid leiomyosarcoma  
8892/3  
8893/3: Bizarre leiomyosarcoma  
8894/0: Angiomyoma  
8894/3: Angiomyosarcoma  
8895/3: Myosarcoma  
8896/3: Myxoid leiomyosarcoma  
8897/1: Smooth muscle tumor, NOS  
8897/3: Malignant tumor of smooth muscle  
8900/0: Rhabdomyoma, NOS  
8900/3: Rhabdomyosarcoma, NOS  
8901/3: Pleomorphic rhabdomyosarcoma, adult type  
8902/3: Mixed type rhabdomyosarcoma  
8904/0  
8910/3: Embryonal rhabdomyosarcoma  
8912/3: Spindle cell rhabdomyosarcoma  
8920/3: Alveolar rhabdomyosarcoma  
8921/3: Rhabdomyosarcoma with ganglionic differentiation  
8930/3: Endometrial stromal sarcoma  
8931/3: Endometrial stromal sarcoma, low grade  
8932/3  
8933/2  
8933/3: Adenosarcoma  
8934/3: Carcinofibroma  
8935/0: Stromal tumor, benign  
8935/3: Stromal sarcoma, NOS  
8936/2: Gastrointestinal stromal tumor, NOS, in situ  
8936/3: Gastrointestinal stromal sarcoma  
8940/0: Pleomorphic adenoma  
8940/2

8940/3: Mixed tumor, malignant, NOS  
8941/2: Carcinoma in situ in pleomorphic adenoma  
8941/3: Carcinoma in pleomorphic adenoma  
8950/3: Mullerian mixed tumor  
8951/3: Mesodermal mixed tumor  
8959/3: Malignant cystic nephroma  
8960/1  
8960/3: Nephroblastoma, NOS  
8963/3: Malignant rhabdoid tumor  
8964/3: Clear cell sarcoma of kidney  
8970/3: Hepatoblastoma  
8971/3: Pancreatoblastoma  
8972/3: Pulmonary blastoma  
8973/3: Pleuropulmonary blastoma  
8974/3  
8980/3: Carcinosarcoma, NOS  
8981/3: Carcinosarcoma, embryonal type  
8982/0  
8982/2  
8982/3: Malignant myoepithelioma  
8983/2: Adenomyoepithelioma, in situ  
8983/3: Adenomyoepithelioma, malignant  
8990/0: Mesenchymoma, benign  
8990/1: Mesenchymoma, NOS  
8990/3: Mesenchymoma, malignant  
8991/3: Embryonal sarcoma  
9000/0: Brenner tumor, NOS  
9000/3: Brenner tumor, malignant  
9013/3: Adenofibroma, malignant  
9014/2: Serous adenocarcinofibroma, in situ  
9014/3: Serous adenocarcinofibroma  
9015/3: Mucinous adenocarcinofibroma  
9020/1: Phyllodes tumor, borderline  
9020/2  
9020/3: Phyllodes tumor, malignant  
9040/0  
9040/3: Synovial sarcoma, NOS  
9041/3: Synovial sarcoma, spindle cell  
9042/3: Synovial sarcoma, epithelioid cell  
9043/3: Synovial sarcoma, biphasic  
9044/3: Clear cell sarcoma, NOS (except of kidney M-8964/3)

9050/3: Mesothelioma, malignant  
9051/0  
9051/3: Fibrous mesothelioma, malignant  
9052/3: Epithelioid mesothelioma, malignant  
9053/3: Mesothelioma, biphasic, malignant  
9055/3: Multicystic mesothelioma, malignant  
9060/3: Dysgerminoma  
9061/2: Seminoma, in situ  
9061/3: Seminoma, NOS  
9062/3: Seminoma, anaplastic  
9063/2: Spermatocytic seminoma, in situ  
9063/3: Spermatocytic seminoma  
9064/0  
9064/1  
9064/2: Intratubular malignant germ cells  
9064/3: Germinoma  
9065/0  
9065/2  
9065/3: Germ cell tumor, nonseminomatous  
9070/2: Embryonal carcinoma, NOS, in situ  
9070/3: Embryonal carcinoma, NOS  
9071/2  
9071/3: Yolk sac tumor  
9072/3: Polyembryoma  
9073/3: Gonadoblastoma, malignant  
9080/0: Teratoma, benign  
9080/1: Teratoma, NOS  
9080/2: Teratoma, in situ  
9080/3: Teratoma, malignant, NOS  
9081/3: Teratocarcinoma  
9082/3: Malignant teratoma, undifferentiated  
9083/3: Malignant teratoma, intermediate  
9084/0: Dermoid cyst, NOS  
9084/1  
9084/3: Teratoma with malignant transformation  
9085/2: Mixed germ cell tumor, in situ  
9085/3: Mixed germ cell tumor  
9090/3: Struma ovarii, malignant  
9091/3: Strumal carcinoid, malignant  
9100/2: Choriocarcinoma in situ, NOS  
9100/3: Choriocarcinoma

9101/2: Choriocarcinoma combined w. other germ cell elements, in situ  
9101/3: Choriocarcinoma combined w. other germ cell elements  
9102/2  
9102/3: Malignant teratoma, trophoblastic  
9103/3: Partial hydatidiform mole, malignant  
9104/3: Malignant placental site trophoblastic tumor  
9105/3: Trophoblastic tumor, epithelioid  
9110/2  
9110/3: Mesonephroma, malignant  
9120/0: Hemangioma, NOS  
9120/1: Hemangioma, NOS, borderline  
9120/3: Hemangiosarcoma  
9121/0: Cavernous hemangioma  
9121/1: Cavernous hemangioma, borderline  
9121/3  
9122/0: Venous hemangioma  
9122/1  
9123/0: Racemose hemangioma  
9124/3: Kupffer cell sarcoma  
9125/0: Epithelioid hemangioma  
9125/3: Epithelioid hemangiosarcoma  
9130/0: Hemangioendothelioma, benign  
9130/1: Hemangioendothelioma, NOS  
9130/3: Hemangioendothelioma, malignant  
9131/0: Capillary hemangioma  
9131/3  
9133/1: Epithelioid hemangioendothelioma, NOS  
9133/3: Epithelioid hemangioendothelioma, malignant  
9135/1  
9136/1: Spindle cell hemangioendothelioma  
9136/3  
9140/3: Kaposi sarcoma  
9150/0: Hemangiopericytoma, benign  
9150/1: Hemangiopericytoma, NOS  
9150/3: Hemangiopericytoma, malignant  
9160/0: Angiofibroma, NOS  
9160/3: Angiofibrosarcoma  
9161/0: Acquired tufted hemangioma  
9161/1: Hemangioblastoma  
9161/3: Hemangioblastoma, malignant  
9170/0: Lymphangioma, NOS

9170/3: Lymphangiosarcoma  
9171/3  
9172/0  
9173/0: Cystic lymphangioma  
9173/3  
9174/3  
9175/3  
9180/0: Osteoma, NOS  
9180/3: Osteosarcoma, NOS  
9181/3: Chondroblastic osteosarcoma  
9182/3: Fibroblastic osteosarcoma  
9183/3: Telangiectatic osteosarcoma  
9184/3: Osteosarcoma in Paget disease  
9185/3: Small cell osteosarcoma  
9186/3: Central osteosarcoma  
9187/3: Introsseous well differentiated osteosarcoma  
9191/0  
9192/3: Parosteal osteosarcoma  
9193/3: Periosteal osteosarcoma  
9194/3: High grade surface osteosarcoma  
9195/3  
9200/0  
9200/1  
9200/3: Malignant, osteosarcoma  
9210/0  
9210/1  
9220/0: Chondroma, NOS  
9220/1  
9220/3: Chondrosarcoma, NOS  
9221/3: Juxtacortical chondrosarcoma  
9230/3: Chondroblastoma, malignant  
9231/3: Myxoid chondrosarcoma  
9240/3: Mesenchymal chondrosarcoma  
9241/0  
9241/3  
9242/3: Clear cell chondrosarcoma  
9243/3: Dedifferentiated chondrosarcoma  
9250/1: Giant cell tumor of bone, NOS  
9250/3: Giant cell tumor of bone, malignant  
9251/1  
9251/3: Malignant giant cell tumor of soft parts

9252/0: Tenosynovial giant cell tumor  
9252/3: Malignant tenosynovial giant cell tumor  
9260/3: Ewing sarcoma  
9261/3: Adamantinoma of long bones  
9262/0  
9270/3: Odontogenic tumor, malignant  
9282/3: Complex odontosarcoma  
9290/3: Ameloblastic odontosarcoma  
9300/0  
9302/3  
9310/3: Ameloblastoma, malignant  
9312/3: Squamous odontogenic tumor, malignant  
9321/3: Central odontogenic fibrosarcoma  
9330/3: Ameloblastic fibrosarcoma  
9340/3  
9341/3  
9342/3: Odontogenic carcinosarcoma  
9350/0: Craniopharyngioma, benign  
9350/1: Craniopharyngioma  
9350/3: Craniopharyngiom, malignant  
9351/0: Craniopharyngioma, adamantinomatous, benign  
9351/1: Adamantinomatous craniopharyngioma  
9351/3: Malignant craniopharyngioma, adamantinomatous  
9352/0: Papillary craniopharyngioma, benign  
9352/1: Papillary craniopharyngioma  
9360/0: Pinealoma, benign  
9360/1: Pinealoma, NOS  
9361/0: Pineocytoma, benign  
9361/1: Pineocytoma  
9361/3: Pineocytoma, malignant  
9362/0  
9362/1  
9362/3: Pineoblastoma  
9363/3: Melanotic neuroectodermal tumor, malignant  
9364/3: Peripheral neuroectodermal tumor  
9365/3: Askin tumor  
9370/0  
9370/1: Chordoma, borderline malignancy  
9370/3: Chordoma, NOS  
9371/3: Chondroid chordoma  
9372/3: Dedifferentiated chordoma

9373/3  
9380/0: Glioma, benign  
9380/1: Glioma, borderline  
9380/3: Glioma, malignant  
9381/0: Gliomatosis cerebri, benign  
9381/1  
9381/3: Gliomatosis cerebri  
9382/0: Mixed glioma, benign  
9382/3: Mixed glioma  
9383/0: Subependymoma, benign  
9383/1: Subependymoma  
9383/3: Subependymoma, malignant  
9384/0: Supependymal giant cell astrocytoma, benign  
9384/1: Supependymal giant cell astrocytoma  
9384/3: Subependymal giant cell astrocytoma, malignant  
9390/0: Choroid plexus papilloma, NOS  
9390/1: Atypical choroid plexus papilloma  
9390/3: Choroid plexus papilloma, malignant  
9391/0: Ependymoma, benign  
9391/1: Ependymoma, borderline  
9391/3: Ependymoma, NOS  
9392/3: Ependymoma, anaplastic  
9393/0: Papillary ependymoma, benign  
9393/1  
9393/3: Papillary ependymoma, NOS  
9394/0: Myxopapillary ependymoma, benign  
9394/1: Myxopapillary ependymoma  
9394/3: Myxopapillary ependymoma, malignant  
9400/0: Astrocytoma, benign  
9400/1: Astrocytoma, borderline malignancy  
9400/3: Astrocytoma, NOS  
9401/0: Astrocytoma, anaplastic, benign  
9401/3: Astrocytoma, anaplastic  
9410/3: Protoplasmic astrocytoma  
9411/0: Gemistocytic astrocytoma, benign  
9411/3: Gemistocytic astrocytoma  
9412/0: Desmoplastic infantile astrocytoma, benign  
9412/1: Desmoplastic infantile astrocytoma  
9412/3  
9413/0: Dysembryoplastic neuroepithelial tumor  
9413/1: Dysembryoplastic neuroepithelial tumor, borderline



9413/3: Dysembryoplastic neuroepithelial tumor, malignant  
9420/0  
9420/3: Fibrillary astrocytoma  
9421/3: Pilocytic astrocytoma, malignant  
9423/3: Polar spongioblastoma  
9424/0  
9424/3: Pleomorphic xanthoastrocytoma  
9430/0  
9430/3: Astroblastoma  
9440/0: Glioblastoma, benign  
9440/1: Glioblastoma, NOS, borderline  
9440/3: Glioblastoma, NOS  
9441/3: Giant cell glioblastoma  
9442/1: Gliofibroma  
9442/3: Gliosarcoma  
9444/0  
9444/1: Chordoid glioma  
9444/3  
9450/0: Oligodendroglioma, NOS, benign  
9450/1: Oligodendroglioma, NOS, borderline  
9450/3: Oligodendroglioma, NOS  
9451/0  
9451/1  
9451/3: Oligodendroglioma, anaplastic  
9460/0  
9460/3: Oligodendroblastoma  
9470/0  
9470/3: Medulloblastoma, NOS  
9471/3: Desmoplastic medulloblastoma  
9472/3: Medullomyoblastoma  
9473/0  
9473/3: Primitive neuroectodermal tumor  
9474/3: Large cell medulloblastoma  
9480/3: Cerebellar sarcoma, NOS  
9490/0: Ganglioneuroma  
9490/1: Ganglioneuroma, borderline  
9490/3: Ganglioneuroblastoma  
9492/0: Gangliocytoma  
9492/1  
9493/0: Dysplastic gangliocytoma of cerebellum  
9500/0: Neuroblastoma, NOS, benign

9500/2: Neuroblastoma, in situ, NOS  
9500/3: Neuroblastoma, NOS  
9501/3: Medulloepithelioma, NOS  
9502/3: Teratoid medulloepithelioma  
9503/0  
9503/3: Neuroepithelioma, NOS  
9504/3  
9505/0: Ganglioglioma, benign  
9505/1: Ganglioglioma, NOS  
9505/3: Ganglioglioma, anaplastic  
9506/0: Central neurocytoma, benign  
9506/1: Central neurocytoma  
9506/3: Neurocytoma, malignant  
9508/3: Atypical teratoid/rhabdoid tumor  
9510/3: Retinoblastoma, NOS  
9511/3: Retinoblastoma, differentiated  
9512/3: Retinoblastoma, undifferentiated  
9513/3: Retinoblastoma, diffuse  
9520/0  
9520/3: Olfactory neurogenic tumor  
9521/3: Olfactory neurocytoma  
9522/3: Olfactory neuroblastoma  
9523/3: Olfactory neuroepithelioma  
9530/0: Meningioma, NOS  
9530/1: Meningiomatosis, NOS  
9530/3: Meningioma, malignant  
9531/0: Meningothelial meningioma  
9531/1: Meningothelial meningioma, borderline  
9531/3: Meningothelial meningioma, malignant  
9532/0: Fibrous meningioma  
9532/1  
9532/3: Fibrous meningioma, malignant  
9533/0: Psammomatous meningioma  
9533/1  
9533/3: Psammomatous meningioma, malignant  
9534/0: Angiomatous meningioma  
9534/1  
9534/3: Angiomatous meningioma, malignant  
9535/0: Hemangioblastic meningioma  
9535/3: Hemangioblastic meningioma, malignant  
9537/0: Transitional meningioma

9537/1  
9537/3: Transitional meningioma, malignant  
9538/0: Clear cell meningioma, benign  
9538/1: Clear cell meningioma  
9538/3: Papillary meningioma  
9539/0: Atypical meningioma, benign  
9539/1: Atypical meningioma, NOS  
9539/3: Meningeal sarcomatosis  
9540/0: Neurofibroma, NOS  
9540/1: Neurofibromatosis, NOS  
9540/3: Malignant peripheral nerve sheath tumor  
9541/0: Melanotic neurofibroma  
9550/0: Plexiform neurofibroma  
9550/3: Plexiform neurofibrosarcma  
9560/0: Neurilemoma, NOS  
9560/1: Neurinomatosis  
9560/3: Neurilemmoma, malignant  
9561/3: MPNST with rhabdomyoblastic differentiation  
9562/0: Neurothekeoma  
9562/3: Neurothekeoma, malignant  
9570/0: Neuroma, NOS  
9570/3  
9571/0: Perineurioma, NOS  
9571/1: Perineurioma, borderline malignancy  
9571/3: Perineurioma, malignant  
9580/0: Granular cell tumor, NOS  
9580/1  
9580/3: Granular cell tumor, malignant  
9581/3: Alveolar soft part sarcoma  
9582/0: Granular cell tumor of the sellar region  
9590/0  
9590/3: Malignant lymphoma, NOS  
9591/3: Malignant lymphoma, non-Hodgkin, NOS  
9596/3: B-cell lymphoma, between diffuse large B and HL (composite HL and NHL)  
9597/3: Primary cutaneous follicle centre lymphoma  
9650/3: Classical Hodgkin lymphoma  
9651/3: Lymphocyte-rich classical Hodgkin lymphoma  
9652/3: Mixed cellularity classical Hodgkin lymphoma  
9653/3: Lymphocyte-depleted classical Hodgkin lymphoma  
9654/3: Hodgkin lymphoma, LD, diffuse fibrosis (OBS 2010+) see 9651/3  
9655/3: Hodgkin lymphoma, lymphocytic depleted, reticular

9659/3: Nodular lymphocyte predominant Hodgkin lymphoma  
9661/3: Hodgkin granuloma (OBS 2010+) see 9651/3  
9662/3: Hodgkin sarcoma (OBS 2010+) see 9651/3  
9663/3: Nodular sclerosis classical Hodgkin lymphoma  
9664/3: Hodgkin lymphoma, nodular sclerosis, cellular phase (OBS) see 9663/3  
9665/3: Hodgkin lymphoma, nodular sclerosis, grade 1 (OBS 2010+) see 9663/3  
9667/3: Hodgkin lymphoma, nodular sclerosis, grade 2 (OBS 2010+) see 9663/3  
9670/3: Malignant lymphoma, small B lymphocytes, NOS (OBS 2010+) see 9823/3  
9671/3: Lymphoplasmacytic lymphoma (NHL)  
9673/3: Mantle cell lymphoma  
9675/3: Malig lymphoma, mixed small & large cell, diffuse (OBS 2010+) see 9690/3  
9678/3: Primary effusion lymphoma  
9679/3: Primary mediastinal (thymic) large B-cell lymphoma  
9680/3: Diffuse large B-cell (NHL) lymphoma (DLBCL)  
9684/3: Malig. lymphoma, large B, diffuse, immunoblastic (OBS 2010+) See 9680/3  
9687/3: Burkitt lymphoma  
9688/3: T-cell histiocyte-rich large B-cell lymphoma  
9689/3: Splenic marginal zone (B-cell) lymphoma  
9690/3: Follicular lymphoma, NOS  
9691/3: Follicular lymphoma, grade 2  
9695/3: Follicular lymphoma, grade 1  
9698/3: Follicular lymphoma, grade 3  
9699/3: Extranodal marginal zone lymphoma of mucosal-assoc. lymphoid tissue-MALT  
9700/3: Mycosis fungoides  
9701/3: Sezary syndrome  
9702/3: Peripheral (mature) T-cell lymphoma, NOS  
9705/3: Angioimmunoblastic T-cell lymphoma  
9708/3: Subcutaneous panniculitis-like T-cell lymphoma  
9709/3: Primary cutaneous T-cell lymphoma  
9712/3: Intravascular large B-cell lymphoma  
9714/3: Anaplastic large cell (T-cell and Null cell) lymphoma, ALK-positive  
9716/3: Hepatosplenic (gamma-delta) T-cell lymphoma  
9717/3: Enteropathy-associated T-cell (intestinal) lymphoma  
9718/3: Primary cutaneous CD30-pos. T-cell (lymphoma) lymphoproliferative disor.  
9719/3: Extranodal NK--/T-cell lymphoma, (nasal and ) nasal type  
9724/3: Systemic EBV pos T-cell lymphoprolif dis of child  
9726/3: Primary cutaneous gamma-delta T-cell lymphoma  
9727/3: Blastic plasmacytoid dendritic cell neoplasm (prec b-cell leuk/lymph)  
9728/3: Precursor B-lymphoblastic lymphoma (OBS 2010+) See 9811/3  
9729/3: Precursor T--cell lymphoblastic lymphoma, NOS (OBS 2010+) See 9837/3  
9731/3: Solitary plasmacytoma of bone/plasmacytoma, NOS

9732/3: Plasma cell (multiple) myeloma  
 9733/3: Plasma cell leukemia (OBS 2010+) See 9732/3  
 9734/3: Extraosseous (extramedullary) plasmacytoma  
 9735/3: Plasmablastic lymphoma  
 9737/3: ALK positive large B-cell lymphoma  
 9738/3: Large B-cell lymph HHV8 multicentric Castleman dis  
 9740/3: Mast cell sarcoma  
 9741/3: Malignant mastocytosis  
 9742/3: Mast cell leukemia  
 9750/1  
 9750/3: Malignant histiocytosis (OBS 2010+) see 9751/3  
 9751/0  
 9751/1: Langerhans cell histiocytosis, NOS  
 9751/3: Langerhans cell histiocytosis (malignant) (NOS)  
 9752/0  
 9752/1: Langerhans cell histiocytosis, unifocal (OBS 2010+) see 9751/3  
 9752/3  
 9753/1  
 9753/3: Langerhans cell histiocytosis, multifocal, malig (OBS 2010+) see 9751/3  
 9754/1: Langerhans cell histiocytosis, disseminated, borderline  
 9754/3: Langerhans cell histiocytosis, disseminated (OBS 2010+) see 9751/3  
 9755/3: Histiocytic sarcoma  
 9756/3: Langerhans cell sarcoma  
 9757/3: Interdigitating dendritic cell sarcoma  
 9758/3: Follicular dendritic cell sarcoma  
 9760/3: Immunoproliferative disease, NOS (OBS 2010+) see 9761/3 or 9762/3  
 9761/3: Waldenstrom macroglobulinemia  
 9762/3: Heavy chain disease  
 9764/3: Immunoproliferative small intestinal disease (OBS 2010+) see code 9762  
 9765/3: Monoclonal gammopathy, malignant  
 9766/1: Angiocentric immunoproliferative lesion  
 9766/3: Angiocentric immunoproliferative lesion, malignant  
 9768/3  
 9769/3: Immunoglobulin deposition disease (malignant)  
 9800/3: Leukemia, NOS  
 9801/3: Acute (undifferentiated) leukemia  
 9805/3: Acute biphenotypic leukemia (OBS 2010+) see codes 9806-9809  
 9806/3: Mixed pheno acute leuk w/t(9;22)(q34;q11.2);BCR-ABL1  
 9807/3: Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged  
 9808/3: Mixed phenotype acute leukemia, B/myeloid, NOS  
 9809/3: Mixed phenotype acute leukemia, T/myeloid, NOS

9811/3: B lymphoblastic leuk/lymph, NOS  
9812/3: B lymphobl leuk/lymph w/t(9;22)(q34;q11.2); BCR-ABL1  
9813/3: B lymphobl leuk/lymph w/t(v;11q23); MLL rearranged  
9814/3: B lymphobl leuk/lymph w/t(12;21)(p13;q22); TEL-AML1  
9815/3: B lymphoblastic leuk/lymph w/hyperdiploidy  
9816/3: B lymphobl leuk/lymph w/hypodiploidy (hypodip ALL)  
9817/3: B lymphobl leuk/lymph w/t(5;14)(q31;q32); IL3-IGH  
9818/3: B lymphobl leuk/lymph w/t(1;19)(q23;p13.3); E2A PBX1  
9820/3: Lymphoid leukemia, NOS  
9823/3: Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-cell)  
9826/3: Burkitt cell leukemia  
9827/3: Adult T-cell leukemia/lymphoma (HTLV-1 pos.)  
9831/3: T-cell large granular lymphocytic leukemia  
9832/3: Prolymphocytic leukemia, NOS  
9833/3: B-cell prolymphocytic leukemia  
9834/3: T-cell prolymphocytic leukemia  
9835/3: Precursor cell lymphoblastic leukemia, NOS (OBS 2010+) see 9811/3  
9836/3: Precursor B-cell lymphoblastic leukemia (OBS 2010+) see code 9811/3  
9837/3: Adult T-cell leukemia/lymphoma  
9840/3: Acute erythroid leukemia (M6 type)  
9860/3: Myeloid leukemia, NOS  
9861/3: Acute myeloid leukemia  
9863/3: Chronic myeloid leukemia, NOS  
9865/3: Acute myeloid leukemia w/t(6;9)(p23;q34) DEK-NUP214  
9866/3: Acute promyelocytic leukemia (AML with t(15;17)(q22;q12)) PML/RARA  
9867/3: Acute myelomonocytic leukemia  
9869/3: Acute myeloid leuk. inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1  
9870/3: Acute basophilic leukemia  
9871/3: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFβ-MYH11  
9872/3: Acute myeloid leukemia with minimal differentiation  
9873/3: Acute myeloid leukemia without maturation  
9874/3: Acute myeloid leukemia with maturation  
9875/3: Chronic myelogenous leukemia, BCR/ABL positive  
9876/3: Atypical chronic myeloid leukemia, BCR/ABL negative  
9891/3: Acute monoblastic and monocytic leukemia  
9895/3: AML with myelodysplasia-related changes (multilineage dysplasia)  
9896/3: Acute myeloid leukemia, t(8;21)(q22;q22) RUNX1-RUNX1T1  
9897/3: Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL  
9898/3: Myeloid leukemia associated w/Down Syndrome  
9910/3: Acute megakaryoblastic leukemia  
9911/3: Acute myeloid leuk (megakaryobl) w/t(1;22)(p13;q13)

9920/3: Therapy-related (acute) myeloid neoplasm  
9930/3: Myeloid sarcoma  
9931/3: Acute panmyelosis with myelofibrosis  
9940/3: Hairy cell leukemia  
9945/3: Chronic myelomonocytic leukemia, NOS  
9946/3: Juvenile myelomonocytic leukemia  
9948/3: Aggressive NK-cell leukemia  
9950/3: Polycythemia vera  
9960/3: Chronic myeloproliferative disease, NOS (OBS 2010+) see 9975/3  
9961/3: Primary myelofibrosis/myelosclerosis with myeloid metaplasia  
9962/3: Essential thrombocythemia  
9963/3: Chronic neutrophilic leukemia  
9964/3: Chronic eosinophilic leukemia (hypereosinophilic syndrome), NOS  
9965/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange  
9966/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange  
9967/3: Myeloid and lymphoid neoplasm w/FGFR1 abnormalities  
9970/1: Lymphoproliferative disorder, borderline  
9970/3: Lymphoproliferative disorder (disease), NOS (malig only prior to 2010)  
9971/3: Polymorphic PTLD  
9975/3: Myelodysp./myeloproliferative neoplasm unclass (malig only before 2010)  
9980/3: Refractory anemia  
9982/3: Refractory anemia with sideroblasts  
9983/3: Refractory anemia with excess blasts  
9984/3: Refractory anemia w. excess blasts in transformation  
9985/3: Refractory cytopenia with multilineage dysplasia  
9986/3: Myelodysplastic syndrome associated with isolated del(5q)  
9987/3: Therapy related myelodysplastic syndrome, NOS (OBS 2010+) See 9920/3  
9989/3: Myelodysplastic syndrome, unclassifiable or NOS  
9991/3: Refractory neutropenia  
9992/3: Refractory thrombocytopenia

*Summary Stage:* single variable based on SEER Summary Stage 77, 2000, Derived  
(combined based on dx year)  
IS, L, R, D, unknown

*Laterality:*

Not a paired site, Right (origin of primary), Left (origin of primary), Only one  
side—side unspecified, Bilateral-single primary, Paired site—midline tumor,  
Paired site—but no information

*Grade:*

Well differentiated; Grade I  
Moderately differentiated; Grade II  
Poorly differentiated; Grade III  
Undifferentiated; anaplastic; Grade  
IV  
T-cell  
B-cell; pre-B; B-precursor  
Null cell; non T-non B  
NK cell; natural killer cell  
Unknown



**ICCC: based on ICD-O-3 regardless of diagnosis date**

**I Leukemias, myeloproliferative & myelodysplastic diseases**

**I(a) Lymphoid leukemias**

**I(b) Acute myeloid leukemias**

**I(c) Chronic myeloproliferative diseases**

**I(d) Myelodysplastic syndrome and other myeloproliferative**

**I(e) Unspecified and other specified leukemias**

**II Lymphomas and reticuloendothelial neoplasms**

**II(a) Hodgkin lymphomas**

**II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)**

**II(c) Burkitt lymphoma**

**II(d) Miscellaneous lymphoreticular neoplasms**

**II(e) Unspecified lymphomas**

**III CNS and misc intracranial and intraspinal neoplasms**

**III(a) Ependymomas and choroid plexus tumor**

**III(b) Astrocytomas**

**III(c) Intracranial and intraspinal embryonal tumors**

**III(d) Other gliomas**

**III(e) Other specified intracranial/intraspinal neoplasms**

**III(f) Unspecified intracranial and intraspinal neoplasms**

**IV Neuroblastoma and other peripheral nervous cell tumors**

**IV(a) Neuroblastoma and ganglioneuroblastoma**

**IV(b) Other peripheral nervous cell tumors**

**V Retinoblastoma**

**VI Renal tumors**

**VI(a) Nephroblastoma and other nonepithelial renal tumors**

**VI(b) Renal carcinomas**

**VI(c) Unspecified malignant renal tumors**

**VII Hepatic tumors**

**VII(a) Hepatoblastoma**

**VII(b) Hepatic carcinomas**

**VII(c) Unspecified malignant hepatic tumors**

**VIII Malignant bone tumors**

**VIII(a) Osteosarcomas**

**VIII(b) Chondrosarcomas**

- VIII(c) Ewing tumor and related sarcomas of bone
- VIII(d) Other specified malignant bone tumors
- VIII(e) Unspecified malignant bone tumors
- IX Soft tissue and other extraosseous sarcomas
  - IX(a) Rhabdomyosarcomas
  - IX(b) Fibrosarcomas, peripheral nerve & other fibrous
  - IX(c) Kaposi sarcoma
  - IX(d) Other specified soft tissue sarcomas
  - IX(e) Unspecified soft tissue sarcomas
- X Germ cell & trophoblastic tumors & neoplasms of gonads
  - X(a) Intracranial & intraspinal germ cell tumors
  - X(b) Extracranial & extragonadal germ cell tumors
  - X(c) Malignant gonadal germ cell tumors
  - X(d) Gonadal carcinomas
  - X(e) Other and unspecified malignant gonadal tumors
- XI Other malignant epithelial neoplasms and melanomas
  - XI(a) Adrenocortical carcinomas
  - XI(b) Thyroid carcinomas
  - XI(c) Nasopharyngeal carcinomas
  - XI(d) Malignant melanomas
  - XI(e) Skin carcinomas
  - XI(f) Other and unspecified carcinomas
- XII Other and unspecified malignant neoplasms
  - XII(a) Other specified malignant tumors
  - XII(b) Other unspecified malignant tumors

Not classified by ICC or in situ

*Report Source:* only 2 codes—other; DCO or autopsy only

*CBTRUS Brain groupings based on site and histology:* Updated by CBTRUS, See Appendix A

*MP based on IARC Rules:* check Y/N

*MP based on SEER Rules:* check Y/N

*County-Level Urban/Rural Status:* Based on Beale codes  
Metro, Non-Metro, unknown

*County-level poverty:* Based on ACS % living in poverty rolling 5 year-average (linked to date of diagnosis)  
<5%, 5-9.9%, 10-19.99%, 20%+, unknown

*SES Composite (SEER):* based on ACS data, county-level not tract because we do not currently have denominator (US only). Components include: Occupation, Unemployment, Poverty, Income, Education, Housing (price, ownership, crowding).

Appendix A. CBTRUS site/histology groups for malignant and non-malignant brain and CNS tumors. The variable is histologic group for malignant (Table 2b) and non-malignant (Table 2c) brain and CNS tumors (based on Table 1).

**Table 1.** Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Site Groupings

Site	ICD-O-3 <sup>a</sup> Site Code
Cerebrum	C71.0
Frontal lobe of brain	C71.1
Temporal lobe of brain	C71.2
Parietal lobe of brain	C71.3
Occipital lobe of brain	C71.4
Ventricle	C71.5
Cerebellum	C71.6
Brain stem	C71.7
Other brain	C71.8-C71.9
Overlapping lesion of brain	C71.8
Brain, NOS	C71.9
Spinal cord and cauda equina	C72.0-C72.1
Spinal cord	C72.0
Cauda equina	C72.1
Cranial nerves	C72.2-C72.5
Olfactory nerve	C72.2
Optic nerve	C72.3
Acoustic nerve	C72.4
Cranial nerve, NOS	C72.5
Other nervous system	C72.8-C72.9
Overlapping lesion of brain and central nervous system	C72.8
Nervous system, NOS	C72.9
Meninges (cerebral & spinal)	C70.0-C70.1, C70.9
Cerebral meninges	C70.0
Spinal meninges	C70.1
Meninges, NOS	C70.9
Pituitary and craniopharyngeal duct	C75.1-C75.2
Pituitary gland	C75.1
Craniopharyngeal duct	C75.2
Pineal gland	C75.3
Olfactory tumors of the nasal cavity <sup>b</sup>	C30.0

<sup>a</sup>International Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.

<sup>b</sup>ICD-O-3 histology codes 9522-9523 only.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.

**Table 2b. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Malignant Histologies<sup>a</sup>**

Histology	ICD-O-3 <sup>b</sup> Histology Code <sup>c</sup>
<b>Tumors of Neuroepithelial Tissue</b>	
Pilocytic astrocytoma*	9421/1 [Included with malignant tumors], 9425/3 <sup>c</sup>
Diffuse astrocytoma*	9400/3, 9410/3, 9411/3, 9420/3
Anaplastic astrocytoma*	9401/3
Unique astrocytoma variants*	9381/3, 9424/3
Glioblastoma*	9440/3, 9441/3, 9442/3
Oligodendroglioma*	9450/3
Anaplastic oligodendroglioma*	9451/3, 9460/3
Oligoastrocytic tumors*	9382/3
Ependymal tumors*	9391/3, 9392/3, 9393/3
Glioma malignant, NOS*	9380/3, 9431/1, 9432/1 [Included with malignant tumors]
Choroid plexus tumors	9390/3
Other neuroepithelial tumors*	9423/3, 9430/3
Neuronal and mixed neuronal-gial tumors*	8680/3, 8693/3, 9505/3, 9522/3, 9523/3
Tumors of the pineal region	9362/3, 9395/3 <sup>c</sup>
Embryonal tumors	8963/3, 9364/3, 9470/3, 9471/3, 9472/3, 9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3
<b>Tumors of Cranial and Spinal Nerves</b>	
Nerve sheath tumors	9540/3, 9560/3, 9561/3, 9571/3
<b>Tumors of Meninges</b>	
Meningioma	9530/3, 9538/3, 9539/3
Mesenchymal tumors	8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 8850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3
Primary melanocytic lesions	8720/3, 8728/3, 8770/3, 8771/3
Other neoplasms related to the meninges	9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3
<b>Lymphomas and Hemopoietic Neoplasms</b>	
Lymphoma	9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3
Other hemopoietic neoplasms	9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3
<b>Germ Cell Tumors and Cysts</b>	
Germ cell tumors, cysts and heterotopias	8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3
<b>Tumors of Sellar Region</b>	
Tumors of the pituitary	8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3
<b>Unclassified Tumors</b>	
Hemangioma	9120/3, 9130/3, 9133/3, 9140/3
Neoplasm, unspecified	8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3
All other	8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3

<sup>a</sup>Includes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definitions.

<sup>b</sup>International Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.

<sup>c</sup>See the CBTRUS website for additional information about the specific histology codes included in each group: <http://www.cbtrus.org>.

\*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.

Table 2c. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Non-Malignant Histologies<sup>a</sup>

Histology	ICD-O-3 <sup>b</sup> Histology Code <sup>c</sup>
<b>Tumors of Neuroepithelial Tissue</b>	
Unique astrocytoma variants*	9384/1
Ependymal tumors*	9383/1, 9394/1
Choroid plexus	9390/0,1
Other neuroepithelial tumors	9363/0, 9444/1
Neuronal and mixed neuronal-glia tumors*	8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1
Tumors of the pineal region	9360/1, 9361/1
Embryonal tumors	9490/0
<b>Tumors of Cranial and Spinal Nerves</b>	
Nerve sheath tumors	9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0
Other tumors of cranial and spinal nerves	9562/0
<b>Tumors of Meninges</b>	
Meningioma	9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1
Mesenchymal tumors	8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0
Primary melanocytic lesions	8728/0,1, 8770/0, 8771/0
Other neoplasms related to the meninges	9161/1, 9220/0,1, 9535/0
<b>Lymphomas and Hemopoietic Neoplasms</b>	
Other hemopoietic neoplasms	9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1
<b>Germ Cell Tumors and Cysts</b>	
Germ cell tumors, cysts and heterotopias	8440/0, 9080/0,1, 9084/0
<b>Tumors of Sellar Region</b>	
Tumors of the pituitary	8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0
Craniopharyngioma	9350/1, 9351/1, 9352/1
<b>Unclassified Tumors</b>	
Hemangioma	9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1
Neoplasm, unspecified	8000/0,1, 8001/0,1, 8005/0, 8010/0
All other	8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0

<sup>a</sup>Includes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definition.

<sup>b</sup>International Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.

<sup>c</sup>See the CBTRUS website for additional information about the specific histology codes included in each group: <http://www.cbtrus.org>.

\*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.